Raynaud's | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

100 results for “Raynaud's”

FDA Grants Fast Track Designation to Yutrepia for Raynaud's Phenomenon in Systemic Sclerosis

Liquidia's YUTREPIA Receives FDA Fast Track Designation for Systemic Sclerosis-Associated Raynaud's Phenomenon

Aisa Pharma's AISA-021 Shows Promise in Phase 2 Trial for Systemic Sclerosis-Associated Raynaud's Phenomenon

PDE4B Emerges as Shared Therapeutic Target Across Tissues in Systemic Sclerosis

UK Government Issues Supply Warnings for Nifedipine and Oxcarbazepine Amid Multiple Brand Shortages

Liquidia Reports Strong YUTREPIA Launch with $148.3M in Full-Year 2025 Sales, Expands Clinical Pipeline

Amneal Launches Brekiya, First Self-Administered DHE Autoinjector for Migraine and Cluster Headaches

FDA Approves First CGRP Antagonist for Pediatric Migraine Prevention as Ajovy Expands to Children

AbbVie's Atogepant Hits Primary and All Eight Secondary Endpoints in Phase III Menstrual Migraine Trial

Kailera Bio Obtains $400M to Fast-Track Obesity Drug into Phase 3 Trials